Compare iShares MSCI Hong Kong ETF (EWH) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Hong Kong ETF vs IDEXX Laboratories, Inc. — how do they compare? iShares MSCI Hong Kong ETF trades at $22.05, while IDEXX Laboratories, Inc. trades at $576.42 (market cap $43.94B). The key difference: iShares MSCI Hong Kong ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| EWH | IDXX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $24.55 | $766.68 |
52-Week Low | $20.15 | $514.61 |
Market Cap | — | $43.94B |
Enterprise Value | — | $44.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWH, the iShares MSCI Hong Kong ETF, trades at $22.04, up 1.71% with a bullish technical signal from moving averages. The ETF tracks Hong Kong equities, showing recent momentum in Chinese technology stocks as highlighted in recent market coverage. Key resistance and support cluster around $22, while RSI readings suggest potential overbought conditions. The fund declared a $0.35 dividend payable in June 2026.
Outlook remains tied to Hong Kong market performance and Chinese economic factors. Positive catalysts include technology sector rallies and Hong Kong's growing wealth hub status, but risks involve regulatory scrutiny on Chinese brokerages and IPO performance concerns. Investor sentiment is cautiously optimistic amid regional market volatility.
IDXX trades at $572.38, up 5.86% over 24 hours, with a neutral technical signal and strong fundamentals. The company reported Q1 2026 EPS of $3.47, beating estimates, and maintains robust profitability with a 24.63% net margin. Revenue growth accelerated to $4.3 billion in 2025, supported by innovation in veterinary diagnostics and AI integration. Cash flow from operations remains healthy at $1.18 billion, though net cash flow was negative $108 million due to financing activities.
Outlook is positive given consistent earnings beats and analyst consensus leaning buy (59% of ratings). Key risks include high valuation multiples (P/E 40.99) and competitive pressures in medical devices. The stock's proximity to its 52-week high suggests momentum but warrants caution on pullbacks. Institutional sentiment is bolstered by product expansions like taeniid tapeworm detection and SDMA integration for kidney disease screening.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Hong Kong ETF
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
